200O Pembrolizumab plus axitinib (pembro + axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia

Kondoh, Chihiro; Bae, Woo Kyun; Tamada, Satoshi; Matsubara, Nobuaki; Lee, H.J.; Mizuno, Ryuichi; Ani, Saad; Kimura, Go; Tomita, Yoshihiko; Ch, Chang; Chang, Jui-Chi; Lin, J.; Perini, Rodolfo F.; Molife, L. Rhoda; Powles, Thomas; Rini, Brian I.; Chung, H-J.

doi:10.1016/j.annonc.2020.10.212

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of racial or ethnic subgroup analyses for OS were unavailable for nine trials, 27–42 and those for PFS were unavailable for six trials 11,13,43–49 . The remaining trials were included in the meta‐analysis ( n = 17, m = 19 for OS 11–13,26,44–65 and n = 11, m = 12 for PFS 12,26,50–65 ).…”

Section: Resultsmentioning

confidence: 99%

“…13,26,27 The results of racial or ethnic subgroup analyses for OS were unavailable for nine trials, [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] and those for PFS were unavailable for six trials. 11,13,[43][44][45][46][47][48][49] The remaining trials were included in the meta-analysis (n = 17, m = 19 for OS [11][12][13]26, and n = 11, m = 12 for PFS 12,26,[50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65] ).…”

Section: Literature Search Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Disparity in survival benefits of pembrolizumab between Asian and non‐Asian patients with advanced cancers: A systematic review and meta‐regression analysis

Peng,

Lin,

Chen

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors have revolutionized the treatment of malignancies. However, disproportionate enrollment among races and ethnicities places the generalizability of global trial results in doubt.MethodsIn this systematic review, phase 3 randomized controlled trials investigating pembrolizumab in advanced cancers and providing subgroup analyses of Asian and non‐Asian participants were included. The primary and secondary effect measures were the mean differences (MDs) in the natural logarithms of the hazard ratios (HRs) for overall survival (OS) and progression‐free survival (PFS) between these two subgroups, respectively. We used random‐effects meta‐analysis to calculate the pooled ratios of HRs (i.e., exp(MD)) and implemented a meta‐regression analysis to identify significant covariates.ResultsA total of 17 and 11 trials were included in the meta‐analyses of OS and PFS, respectively. These trials included 2732 (25.49%) Asian and 7000 (65.32%) non‐Asian participants in the OS analysis and 1438 (22.5%) Asian and 4129 (64.61%) non‐Asian participants in the PFS analysis. The pooled ratio of HRs for OS was 0.87 (95% CI: 0.76–0.99; p = 0.0391), favoring Asian participants, but no significant difference was found in PFS (pooled ratio of HRs: 0.93; 95% CI: 0.82–1.07; p = 0.2391). Both linear meta‐regression analyses revealed an open‐label design as a crucial covariate, which indicated more benefits for non‐Asian participants.ConclusionsCompared with non‐Asian patients, Asian patients with advanced cancers may derive superior OS benefits from pembrolizumab. Although the results warrant further exploration, this meta‐analysis provides insight into clinical research design.

show abstract